Key facts
- This page summarizes Robin Kramer's Form 4 filing for BIOGEN INC. (BIIB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jul 2022, 19:33.
Robin Kramer - 01 Jul 2022 Form 4 Insider Report for BIOGEN INC. (BIIB)
- Reporting relationship
- Chief Accounting Officer
- Issuer ticker
- BIIB
- Reported as of
- 01 Jul 2022
- Net transaction value
- -$15,587
- SEC form
- 4
- Accepted by SEC
- 06 Jul 2022, 19:33:02 UTC
- Prior SEC filing
- 15 Apr 2022
- Next SEC filing
- 12 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Wendell Taylor, attorney-in-fact for Robin Kramer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robin Kramer filed Form 4 for BIOGEN INC. (BIIB) on 06 Jul 2022.
Change
- Previous filing in this sequence was filed on 15 Apr 2022.
- Current net transaction value: -$15,587.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIIB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +252
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 2,092
- Date
- 01 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
BIIB
transaction
Common Stock
Tax liability
- Transaction value
- $15,587
- Shares
- -74
- Change %
- -3.5%
- Price
- $210.63
- Shares after
- 2,018
- Date
- 01 Jul 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIIB
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -252
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 252
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 252
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan.
Footnote F2
The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 07/01/2020.